You can buy or sell ADCT and other stocks, options, ETFs, and crypto commission-free!
ADC Therapeutics SA, also called ADC Therapeutics, is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. Read More The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland. The listed name for ADCT is ADC Therapeutics SA.
52 Week High
52 Week Low
— per share
Expected Nov 2, Pre-Market